28.9 billion yuan! These Chinese pharmaceutical companies favorite | 'buy buy buy'

Recently, PricewaterhouseCoopers released a report showing that in the first half of 2017, overseas investment transactions by Chinese companies in the pharmaceutical sector reached 4.353 billion U.S. dollars (about 28.95 billion yuan), a compound annual growth rate of 85%.

As of the first three quarters, 32 cases of cross-border mergers and acquisitions have taken place in the pharmaceutical industry.

It has been reported that in the recent three years, private-owned enterprises dominated the overseas pharmaceutical M & A market with a total transaction volume of 21 times that of state-owned enterprises health The developed North American and European regions are the primary investment destinations for Chinese enterprises in recent years.

According to the "Cross-border M & A Trends Report of the First Three Quarters of 2017", according to Yi Jie, 32 cases of cross-border mergers and acquisitions occurred in the healthcare sector in the first three quarters of this year, 9 more than the same period in 2016.

In May 2017, Tasly and Pharnext S.A. signed an agreement to cooperate in drug discovery and development for Gene Networks. Tasly invested 20 million euros in Pharnext and the two companies intend to carry out a number of cooperation projects including equity investment and clinical research.

At the same time, human welfare medicine also announced plans to acquire its global subsidiary, including Jasper, Sexuality Health Industry Business Assets.

In June 2017, the cross-border transaction of private-owned Sanpower Group's acquisition of 100% of Danone Lyon, the biomedical company from Valeant, was also completed.

In September 2017, Ireland ophthalmology completed the acquisition of ophthalmic equity of Bavaria in Europe with 152 million euros, achieving nearly 87% of the holding of ophthalmic Bavaria.

In October 2017, Fosun Pharma announced the completion of the acquisition of a 74% stake in India's pharmaceutical company GlandPharma for a consideration of 1.091 billion U.S. dollars.

Soon after, HiPurim announced that it would subscribe for a new issue of no more than 60,416,667 ordinary shares of Resverlogix Corp. (RVX), a Canadian pharmaceutical company, with its own capital not exceeding RMB 460 million.

Time goes back to December 2016. Relevant agencies of the state said they will pay close attention to the recent tendency of "irrational outward investment" in real estate, hotels, cinemas, entertainment industry and sports clubs.

For a time, limited investment in the pan-entertainment sector, the direction of overseas investment in medicine.

On August 18, 2017, the state released the Circular on Guiding Opinions on Further Guiding and Standardizing the Orientation of Overseas Investment, which explicitly states that domestic enterprises should be restricted from overseas investment in real estate, hotels, cinemas, entertainment industry and sports clubs.

It has been revealed that regulators already have policy guidelines on the overseas investment route for large enterprises, such as the Belt and Road Initiative.

Insiders analysis, Fosun and other overseas investment in enterprises from the past real estate, entertainment and other industries, medicine and other fields, is to adapt to the policy to make strategic adjustments.

Of course, in the global M & A market, the pharmaceutical industry has also been a hot area.A researcher from the pharmaceutical industry analyzed that the pharmaceutical industry belongs to a capital-intensive and technology-intensive industry with high barriers and strict supervision and there is a great deal of new drug research and development Certainty, through the mergers and acquisitions can spread the risk and speed up the project.

In the Johnson & Johnson, Pfizer and other large pharmaceutical companies in the international development process, mergers and acquisitions almost none absent.According to the relevant research company analysis report, our country medicine Market concentration needs to be further improved.

In China's listed pharmaceutical companies, the highest market value of Hengrui Medicine (market value of about 200 billion yuan) and Johnson still have more than 100 billion US dollars gap.

Visible, China's pharmaceutical industry to emerge a real giants need to cross-border mergers and acquisitions, to promote enterprise Internationalization, grafting advanced foreign technology, looking for new markets, enhance their competitiveness.

Just do not know, under the M & A giant who jumped out of the water?